Sanofi-Aventis signs $750 million microRNA deal with Regulus
Sanofi-Aventis has signed a development and commercialisation deal with Regulus Therapeutics that could be worth up to $750 million to the microRNA-focused biopharmaceutical company.
Sanofi-Aventis has signed a development and commercialisation deal with Regulus Therapeutics that could be worth up to $750 million to the microRNA-focused biopharmaceutical company.